In the framework of its partnership with the Institute Pasteur, CIB, BNP Paribas’ Corporate and Investment Banking branch,  supports a collaborative research between the Indonesia’s Eijkman Institute and the Biomedical Parasitology Unit of Institute Pasteur Paris. The project aims at establishing a novel malaria vaccine.

The new vaccine, created by the joint efforts of the two teams, has already been successfully tested on phase I in Switzerland, Burkina Faso, Tanzania, and Mali.
Malaria remains a major threat all over the highly populated Southeast Asian countries, such as Thailand, Burma, Cambodia, Vietnam, Malaysia, Indonesia, Philippines, and also India. Most Malaria vaccine candidates are today only tested in Africa, thus risking to not be effective for other regions threatened by the disease. What makes this vaccine unique is the fact that it is developped in Southeast Asia, and tested all around the world.  

In perspective, the Indonesian-French research team is currently looking for locations for phase II trials, and several districts have already been identified: Lampung, South Sumatra, West Sumba and the eastern Lesser Sundas archipelago.

Louis Pasteur himself once wrote that « Science does not have a country, or rather, the country of science is the entire human kind » which inspired the extensive international activity of the Institute. Similarly, CIB’s sponsorship extends to a multitude of projects, among which research groups in Brazil and Colombia, also working on malaria.